Ventyx Biosciences reported its financial results for the first quarter of 2025, with a cash, cash equivalents, and marketable securities balance of $228.8 million as of March 31, 2025. This financial position is expected to fund planned operations into at least the second half of 2026. The company continues to manage its resources to support its clinical development programs.
The company reiterated its expectations for key Phase 2 data readouts throughout 2025. Topline data from the VTX3232 study in patients with early Parkinson’s disease is anticipated in the second quarter of 2025. This is a significant milestone for its CNS-penetrant NLRP3 inhibitor.
Additionally, Ventyx expects to release results from the Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors in the second half of 2025. Results from the Phase 2 trial of VTX2735 in patients with recurrent pericarditis are also expected in the second half of 2025, advancing its peripheral NLRP3 inhibitor.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.